REPRISE study confirms tolvaptan efficacy
The first clinical trial of Tolvaptan showed that it was effective in slowing the growth of the total kidney volume (TKV*) and in slowing the decline in eGFR* in ADPKD patients. However, that trial focussed on patients in the early stages of their disease process. Now there is evidence that Tolvaptan also works in patients at the later stages of ADPKD.